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Abstract: One approach to combat the increasing incidence of multidrug-resistant (MDR) bacterial
pathogens involves repurposing existing compounds with known safety and development pathways
as new antibacterial classes with potentially novel mechanisms of action. Here, triclabendazole
(TCBZ), a drug originally developed to treat Fasciola hepatica (liver fluke) in sheep and cattle, and later
in humans, was evaluated as an antibacterial alone or in combination with sub-inhibitory concentra-
tions of polymyxin B (PMB) against clinical isolates and reference strains of key Gram-positive and
Gram-negative bacteria. We show for the first time that in vitro, TCBZ selectively kills methicillin-
sensitive and methicillin-resistant Staphylococcus aureus and Staphylococcus pseudintermedius at a
minimum inhibitory concentration (MIC) range of 2–4 µg/mL, and vancomycin-resistant enterococci
at a MIC range of 4–8 µg/mL. TCBZ also inhibited key Gram-negative bacteria in the presence of sub-
inhibitory concentrations of PMB, returning MIC90 values of 1 µg/mL for Escherichia coli, 8 µg/mL for
Klebsiella pneumoniae, 2 µg/mL for Acinetobacter baumannii and 4 µg/mL for Pseudomonas aeruginosa.
Interestingly, TCBZ was found to be bacteriostatic against intracellular S. aureus but bactericidal
against intracellular S. pseudintermedius. Additionally, TCBZ’s favourable pharmacokinetic (PK) and
pharmacodynamic (PD) profile was further explored by in vivo safety and efficacy studies using a
bioluminescent mouse model of S. aureus sepsis. We show that repeated four-hourly oral treatment
of mice with 50 mg/kg TCBZ after systemic S. aureus challenge resulted in a significant reduction
in S. aureus populations in the blood to 18 h post-infection (compared to untreated mice) but did
not clear the bacterial infection from the bloodstream, consistent with in vivo bacteriostatic activity.
These results indicate that additional pharmaceutical development of TCBZ may enhance its PK/PD,
allowing it to be an appropriate candidate for the treatment of serious MDR bacterial pathogens.
Keywords: multidrug resistance; triclabendazole; polymyxin B; bacterial pathogens; bioluminescence;
sepsis
1. Introduction
The increasing public health threat posed by antimicrobial resistance (AMR) and the
rise in the incidence of multidrug-resistant (MDR) bacterial pathogens has stimulated novel
research strategies to combat MDR infections. However, the discovery, development and
marketing approval process for new drugs is very challenging and can cost over 2.8 billion
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USD and take over 10 years to reach the market [1]. There is a high risk of failure (82.7%)
in the preclinical stage alone, which may take up to 6 years [2–4].
Repurposing currently registered drugs for new indications is one of the alternative ap-
proaches to overcoming these challenges whilst adhering to the principles of antimicrobial
stewardship [5–8]. Using existing drugs with known toxicological and pharmacokinetic
profiles and an acceptable level of safety and tolerability is a much cheaper and efficient
option than developing entirely new antibiotics [9–11] and has become a more common
strategy in recent years [4,12–14]. One such agent is triclabendazole (TCBZ), a benzim-
idazole anthelminthic agent, with narrow spectrum activity against trematodes in the
genus Fasciola, approved for use in animals (especially cattle, sheep and goats) [15–17]
and humans [18–20]. TCBZ has previously been identified as having potential antibacterial
activity against Gram-positive bacteria when it was included in a mass screening of Food
and Drug Administration (FDA)-approved non-antibacterial drugs [21], and has more
recently been shown to have anticlostridial activity [22].
The mechanism by which TCBZ exhibits its effect against Fasciola species is not fully
elucidated. Both in vitro and in vivo studies suggest that TCBZ and its metabolites (sul-
foxide and sulfone) are absorbed across the tegument of immature and mature worms,
leading to a decrease in the resting membrane potential, inhibition of tubulin function
and inhibition of protein and enzyme synthesis. These metabolic disturbances are asso-
ciated with inhibition of motility, disruption of cell wall ultrastructure and inhibition of
spermatogenesis and vitelline cells [18].
Given indications that TCBZ has potential as an antibacterial agent, to our knowledge,
there have been no published studies that directly demonstrate this potential in vivo. A
preliminary evaluation of in vitro efficacy of a variety of TCBZ derivatives was therefore
carried out against representative Gram-positive (methicillin-resistant and methicillin-
susceptible Staphylococcus spp., vancomycin-resistant Enterococcus spp. and Streptococcus
pneumoniae) and Gram-negative organisms (Escherichia coli, Klebsiella pneumoniae, Pseu-
domonas aeruginosa and Acinetobacter baumannii), including in the presence of polymyxin
B (PMB). PMB was used as it is a well-known Gram-negative outer membrane perme-
abilizer [23,24] and because we have successfully used it for this purpose in previous
published work [25]. From the collection of TCBZ and metabolites, TCBZ was chosen as
the most active, and further antibacterial activity was explored in vitro. Efficacy testing
using a mouse bioluminescent S. aureus infection model was also undertaken to better
investigate its antibacterial properties in vivo.
2. Materials and Methods
2.1. Antimicrobial Agents
TCBZ and four derivatives (TCBZ-SH, TCBZ-SO, TCBZ-SO2 and TCBZ-OH; Figure 1)
were prepared by conjugation of 5-chloro-2-nitroaniline [26] with 2,3-dichlorophenol [27],
followed by reduction to the diamine using sodium dithionite and cyclization, which
gave TCBZ-SH [28]. TCBZ-SO and TCBZ-SO2 were prepared by oxidation with hydrogen
peroxide in a mixture of acetic acid and chloroform at a ratio of 4:1, while TCBZ-OH was
prepared by reaction of the diamine with potassium cyanate [29]. These analogs were
stored in a sealed sample container out of direct light at 4 ◦C in the Microbiology Laboratory
at Clinical and health Sciences, City East Campus, University of South Australia, Australia.
PMB was prepared as a stock solution of 25.6 mg/mL in DMSO, stored in 1 mL
aliquots at −80 ◦C and defrosted immediately prior to use. TCBZ as Fasinex® 240 Oral
Flukicide for Cattle (240 g/L) was purchased from Elanco Australia Pty Ltd (Macquarie
Park, NSW, Australia) and stored at room temperature in the original container, tightly
closed in a cool dry place. Fresh stock solutions of TCBZ (50 mg/kg and 10 mg/kg) were
prepared as oral treatments and diluted in phosphate-buffered saline (PBS) with vigorous
mixing. Moxifloxacin hydrochloride was purchased from Bayer Ltd. as Avelox 400 mg in
a 250 mL solution (equivalent to 1.6 mg/mL moxifloxacin hydrochloride) and stored at
room temperature.
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Figure 1. TCBZ and related synthetic precursor, oxidation and hydrolytic analogs. 
PMB was prepared as a stock solution of 25.6 mg/mL in DMSO, stored in 1 mL ali-
quots at −80 °C and defrosted immediately prior to use. TCBZ as Fasinex®  240 Oral 
Flukicide for Cattle (240 g/L) was purchased from Elanco Australia Pty Ltd (Macquarie 
Park, NSW, Australia) and stored at room temperature in the original container, tightly 
closed in a cool dry place. Fresh stock solutions of TCBZ (50 mg/kg and 10 mg/kg) were 
prepared as oral treatments and diluted in phosphate-buffered saline (PBS) with vigorous 
mixing. Moxifloxacin hydrochloride was purchased from Bayer Ltd. as Avelox 400 mg in 
a 250 mL solution (equivalent to 1.6 mg/mL moxifloxacin hydrochloride) and stored at 
room temperature. 
2.2. Bacterial Strains 
A total of 138 bacterial isolates (55 Gram-positive and 83 Gram-negative) were col-
lected from government, private and university diagnostic laboratories throughout Aus-
tralia (Table S1). The Gram-positive bacterial collection included 4 vancomycin-resistant 
enterococci (VRE), 24 S. aureus isolates (including 21 methicillin-resistant S. aureus 
(MRSA)), 2 S. pneumoniae, 13 S. pseudintermedius (including 10 methicillin-resistant S. 
pseudintermedius (MRSP)), 3 coagulase-negative Staphylococcus spp. (CoNS) and 9 Strepto-
coccus spp. isolates from cases of bovine mastitis. The Gram-negative bacteria collection 
included 21 E. coli, 20 K. pneumoniae, 18 A. baumannii, 20 P. aeruginosa, 2 Neisseria meningit-
idis and 2 N. gonorrhoeae isolates. All organisms were identified to species level using bio-
chemical testing and Matrix-Assisted Laser Desorption/Ionization Time-of-Flight 
(MALDI-TOF) mass spectrometry (MicroflexTM LT/SH BioTyper Bruker Daltonics, Leip-
zig, Germany) at the Australian Centre for Antimicrobial Resistance Ecology (ACARE), 
The University of Adelaide, Australia. 
2.3. Minimum Inhibitory Concentration (MIC) Determination 
Minimum inhibitory concentrations (MICs) were determined in round-bottom 96-
well microtiter trays (Sarstedt 82.1582.001; Mawson Lakes, SA, Australia), using the mod-
ified broth microdilution method recommended by the Clinical and Laboratory Standards 
Institute [30]. Testing concentrations were as follows: TCBZ-256 to 0.25 µg/mL; PMB-32 to 
0.06 µg/mL. Cation-adjusted Mueller–Hinton broth (CAMHB; Becton Dickinson, Sparks, 
MD, USA) was used for MIC testing against all organisms except S. pneumoniae and other 
Streptococcus spp., for which CAMHB supplemented with 3% lysed horse blood and 5% 
horse serum was used. To test the effect of ultra-heat-treated (UHT) milk on the MICs of 
Figure 1. TCBZ and related synthetic precursor, oxidation and hydrolytic analogs.
2.2. Bacterial Strains
A total of 138 bacterial isolates (55 Gram-positive and 83 Gram-negative) were col-
lected from government, private and university diagnostic laboratories throughout Aus-
tralia (Table S1). The Gram-positive bacterial collection included 4 vancomycin-resistant
enterococci (VRE), 24 S. aureus isolates (including 21 methicillin-resistant S. aureus (MRSA)),
2 S. pneumoniae, 13 S. pseudintermedius (including 10 methicillin-resistant S. pseudintermedius
(MRSP)), 3 coagulase-negative Staphylococcus spp. (CoNS) and 9 Streptococcus spp. iso-
lates from cases of bovine mastitis. The Gram-negative bacteria collection included 21
E. coli, 20 K. pneumoniae, 18 A. baumannii, 20 P. aeruginosa, 2 Neisseria meningitidis and 2
N. gonorrhoeae isolates. All organisms were identified to species level using biochemical
testing and Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF)
mass spectrometry (MicroflexTM LT/SH BioTyper Bruker Daltonics, Leipzig, Germany) at
the Australian Centre for Antimicrobial Resistance Ecology (ACARE), The University of
Adelaide, Australia.
2.3. Minimum Inhibitory Concentration (MIC) Determ ation
Minimum inhibitory concentrations (MICs) were determined in round-bottom 96-well
microtiter trays (Sarstedt 82.1582.001; Mawson Lakes, SA, Australia), using the modified
broth microdilution method recommended by the Clinical and Laboratory Standards
I stitute [30]. Testing concentrations were as follows: TCBZ-256 to 0.25 µg/mL; PMB-
32 to 0.06 µg/mL. Cation-adjusted Mueller–Hinton broth (CAMHB; Becton Dickinson,
Sparks, MD, USA) w s used for MIC testing against all organisms except S. pneumoniae and
other Streptococcus pp., for which CAMHB supplemented with 3% lysed horse blood and
5% horse serum was used. To test the effect of ultra-heat-treat d (UHT) mi k on the MICs
of TCBZ against Streptococcus spp., CAMHB supplemented with 3% lysed horse blood and
10% UHT milk was used. To test the effect of pH on the MICs of TCBZ against Streptococcus
spp., RPMI 1640 medium (Sigma-Aldrich, NSW, Australia) was used instead of CAMHB.
Serial two-fold dilutions of the compounds ere perfor ed in 100% DMSO, with
1 µL added to each well. In selected experiments, the MICs for ampicillin, daptomycin,
gentamicin and apramycin against each isolate were determined as an internal quality
control. The MICs against all isolates were determined by visual reading and using an
EnSpire Multimode Plate Reader 2300 (PerkinElmer) at A600 nm. MIC50, MIC90 and MIC
ranges for TCBZ, PMB or combinations were then determined [31].
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2.4. Synergy Testing by Checkerboard Microdilution and Dose Reduction Analysis
The potential activity of TCBZ against clinical and ATCC Gram-negative pathogens
was determined in the presence or absence of 0.25–128 µg/mL PMB in a modified standard
checkerboard assay as described previously [32,33]. Briefly, antimicrobial stock solutions
were prepared at a concentration of 12.8 mg/mL in DMSO for TCBZ and 12.8 mg/mL in
Milli-Q water for PMB. Then, a two-fold serial dilution of each antimicrobial stock solution
was prepared in its appropriate solvent from wells 12 to 3 (from 12.8 to 0.25 mg/mL) and
1 µL of each concentration was added to each well in the challenge plate using an electronic
multichannel pipette followed by 89 µL of the LB broth. Thereafter, 10 µL of bacterial
suspension of approx. 2 × 106 colony-forming units per milliliter (CFU/mL) was added to
each well of the plate, which was subsequently incubated at 37 ◦C for 24 h.
The fractional inhibitory concentration index (FICI) described the results of combi-
nation and was calculated as follows: FICI of combination = FIC A + FIC B. Where FIC
A is the MIC of TCBZ in the combination/MIC of TCBZ alone, FIC B is the MIC of PMB
in the combination/MIC of PMB alone [25,33]. The results indicate synergism when the
corresponding FICI ≤ 0.5, additivity when 0.5 < FICI ≤ 1, indifference when 1 < FICI ≤ 4
and antagonism when the FICI > 4. In this study, the FICI for TCBZ and PMB against
Gram-negative bacteria was calculated to be zero (e.g., 1 ÷ > 256 = 0) where they did
not show any antibacterial activity alone against Gram-negative bacteria at the highest
concentration (256 µg/mL).
The dose-reduction index (DRI) shows the difference between the effective doses
in combination in comparison to its individual dose. DRI was calculated as follows:
DRI = MIC of drug alone/MIC of drug in combination. Given that TCBZ did not show
any antimicrobial activity against the majority of Gram-negative bacteria, the highest
concentration of each compound tested against each isolate was used as its MIC alone
for calculating the DRI (e.g., MIC of TCBZ alone against E. coli 10763 was > 256 µg/mL
and its MIC in combination with PMB was 1 µg/mL; DRI = 256/1). DRI is significant
clinically when the dose reduction is associated with a toxicity reduction without changing
efficacy [34]. Commonly, a DRI higher than 1 is considered beneficial.
2.5. Minimum Bactericidal Concentration (MBC) Determination
The minimum bactericidal concentration (MBC) for TCBZ against Gram-positive bac-
teria alone or against Gram-negative bacteria (in combination with PMB) were determined
as follows. Briefly, 10 µL aliquots from each duplicate well from the MIC assays (starting
from the MIC for each compound) were inoculated onto a sheep blood agar (SBA) plate
and incubated at 37 ◦C. Plates were examined at 24 and 48 h and the MBC was recorded as
the lowest concentration of each test compound at which a 99.9% colony count reduction
was observed on the plate [34].
2.6. Time-Dependent Killing Assays
Time-kill assays were performed (in duplicate) for TCBZ against Gram-positive bacte-
ria (MRSP-1, S. aureus ATCC 29213 and VRE 35C) and for TCBZ in the presence of PMB
against Gram-negative bacteria (E. coli ATCC 25922) as described previously [34]. Briefly, a
few colonies of each strain from overnight SBA plates were emulsified in normal saline and
adjusted to A600 nm = 0.10 (equivalent to approx. 5 × 107 CFU per mL) and the bacterial
suspensions were further diluted 1:20 in saline. TCBZ and PMB were serially diluted
in 100% DMSO or Milli-Q water at 100 × the final desired concentration and a 100 µL
aliquot of each appropriate concentration was added to each 10 mL preparation. TCBZ
and PMB solutions were prepared in 10 mL volumes at 1 × MIC, 2 × MIC and 4 × MIC
concentrations in LB broth. After adding inoculum dose to each tube, duplicate cultures
were incubated at 37 ◦C, with samples withdrawn at 0, 0.5, 1, 2, 4, 6, 8 and 24 h, serially
diluted 10-fold and plated on SBA overnight at 37 ◦C for bacterial enumeration. According
to CLSI, an antimicrobial agent is considered bactericidal if it causes a ≥ 3 × log10 (99.9%)
reduction in colony-forming units per milliliter (CFU/mL) after 18–24 h of incubation,
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and the combination is considered synergistic when it causes a ≥ 2 × log10 reduction in
CFU/mL.
2.7. Multi-Sub-Culture Resistance Selection
Multi-sub-culture resistance selection studies (21 days sequential culturing of S. aureus
ATCC 29213) were undertaken using enrofloxacin as a control antibiotic, as described
previously [35]. Each day an MIC test concentration range of antibiotics from 0.25 to
8 µg/mL on 48 well plates was used. On the first day, the same method described for
MIC microdilution was used to determine the MIC and the plate was incubated at 37 ◦C
for 24 h. Sub-cultures were performed at 24 h intervals for up to 21 days by transferring
20 µL aliquot of culture, containing 5 × 105 CFU, from the well nearest the MIC (usually
1 to 2 dilutions below) which had the same turbidity as antibiotic-free controls. During
the sub-culture, the resistant mutants that emerged were stored at −80 ◦C for subsequent
analysis.
2.8. Intracellular MIC Testing
The mouse J774A.1 macrophage cell line was maintained in DMEM (Dulbecco’s
Modified Eagle Medium) with heat-inactivated fetal bovine serum in cell culture flasks
(75 cm2), as described previously [36]. Cells were allowed to grow to 90% confluency and
were then passaged and transferred to a 48-well cell culture plate. Cells were then allowed
to grow up to a concentration of 5–8 × 105 cells/mL.
S. aureus strain ATCC 29213 was sub-cultured on SBA and incubated at 37 ◦C for
18–20 h. A number of isolated colonies were then resuspended in RPMI medium, adjusted
to 0.5 McFarland standard and opsonized in 10% freshly collected human serum (stored at
−80 ◦C until use) at 37 ◦C for 30 min. Cell culture medium was replaced with the opsonized
bacterial suspension to allow phagocytosis at 37 ◦C for 1 h at a macrophage:bacterium ratio
of 1:2. Macrophage cells were then washed twice in DMEM to remove extracellular bacteria
and exposed to TCBZ at concentrations ranging from 0.5–32 µg/mL, while cells were also
exposed to monensin at concentrations ranging from 0.25–16 µg/mL as a control. At this
stage, 50 µg/mL gentamicin was added to kill any remaining extracellular bacteria and the
infected macrophage cells were incubated for a further 20–24 h. After incubation, infected
macrophage cells were washed with PBS three times to remove any carryover antibiotics
and then collected by scraping. Two protocols were then undertaken in parallel: (i) after
1:10, 1:100 and 1:1000 dilutions, 10 µL aliquots of the harvested cells were spot-plated onto
SBA for determination of CFU. Plates were then incubated at 37 ◦C for 24 h. The colonies
were counted the next day and CFUs were determined. (ii) The protein concentration was
determined as per manufacturer’s instructions with bovine serum albumin as a standard
(DC protein assay kit, Bio-Rad Catalog No 500-0112). All results were then calculated as
CFU/mg of cell protein and these values were plotted using ‘R’ software (version: 3.6.1).
2.9. Haemolysis Assay
This was performed using fresh human red blood cells (RBCs) from donors as de-
scribed previously [25,37]. Fresh RBCs were washed in PBS three times at 500 × g for 5 min,
and then resuspended 1% (w/v) in PBS. Serial two-fold dilutions of each compound (2 µL
each) were added into the respective wells, in quadruplicates, in a round-bottom 96-well
microtiter tray (Sarstedt 82.1582.001; Mawson Lakes, SA, Australia), starting at 128 µg/mL
for each compound using ampicillin as a control. Thereafter, 198 µL of the 1% RBC solution
was added to each well, and the mixture was incubated for 1 h at 37 ◦C with shaking at
100 rpm. Quadruplicate wells containing either 1% Triton X100 or PBS only served as
controls. After incubation, the trays were centrifuged at 1000 × g for 3 min and 100 µL
of supernatant from each well was transferred into a new 96-well tray. Absorbance was
measured at A450nm on a Cytation 5 Cell Imaging Multi-Mode Reader (BioTek, Millennium
Science Pty Ltd., Mulgrave, VIC, Australia) and plotted against each dilution. Hemolytic
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titer was determined as the reciprocal of the dilution at which 50% of erythrocytes were
lysed at A450nm.
2.10. In Vitro Cytotoxicity Assays
We assayed TCBZ for in vitro cytotoxicity using a panel of adherent mammalian cell
lines hEK293 (human embryonic kidney cell line), Detroit 562 (human nasopharyngeal
carcinoma epithelial cell line) and MCF-7 (human mammary gland adenocarcinoma cell
line), as described previously [35]. Assays were performed in duplicates in flat-bottom
black 96-well tissue culture trays (Costar) seeded with ~1 × 104 cells per well. After 24 h
incubation, media was removed, washed once with medium without antibiotics and fresh
medium supplemented with 10% (vol/vol) FBS was added. Viability of each cell line in the
presence of each compound was assessed starting at 64 µg/mL (for hEK293 and Detroit
562 cell lines) or starting at 16 µg/mL (for MCF-7) at 1 h intervals for 20 h at 37 ◦C and in
5% CO2 on a Cytation 5 Cell Imaging Multi-Mode Reader (BioTek, Millennium Science Pty
Ltd., Mulgrave, VIC, Australia) using the RealTime-Glo™ MT Cell Viability Assay reagent
(Promega, Madison, WI, USA).
2.11. Ethics Statements
For TCBZ safety and efficacy testing experiments, outbred 5- to 6-week-old male
CD1 (Swiss) mice (weighing between 25 g to 32 g) obtained from the Laboratory Animal
Services breeding facility of the University of Adelaide were used. Mice had access to
food and water ad libitum throughout the experiments. The Animal Ethics Committee
of The University of Adelaide (approval number S-2015-151) reviewed and approved all
animal experiments. The studies were conducted in compliance with the Australian Code
of Practice for the Care and Use of Animals for Scientific Purposes (8th Edition 2013) and
the South Australian Animal Welfare Act 1985.
2.12. Oral Safety Assessment of TCBZ following Parenteral Administration
Mice were placed in individually ventilated cages in 3 treatment groups as follows:
(i) 10 mg/kg of TCBZ (n = 3); (ii) 50 mg/kg of TCBZ (n = 3); (iii) PBS (n = 3); and (iv)
1.6 mg/mL of moxifloxacin (n = 3). Mice in group (i) were treated with a total of 25 µL of
10 mg/kg of TCBZ. Mice in group (ii) were treated with 125 µL of 50 mg/kg of TCBZ, mice
in group (iii) were treated with 25 µL of PBS while mice in group (iv) were treated with
a total of 94 µL of moxifloxacin. All mice were treated three times per day for 5 days. At
the conclusion of the experiment (5 days from the start), mice were humanely killed and
sections of tissues (lung, heart, liver, spleen, kidney and small intestinal) were collected
and subjected to histopathological analysis.
2.13. Histopathological Examination
Mouse tissues (including lung, heart, liver, spleen, kidney and small intestinal) col-
lected from the oral safety challenge were fixed in 10% neutral-buffered formalin and
processed routinely. The specimens were embedded in paraffin blocks and sections of 4 µm
thickness were cut using a microtome. Hematoxylin and Eosin staining of the sections were
performed and the slides were observed and recorded under light microscopy.
2.14. Oral Efficacy Testing of TCBZ following Systemic Challenge of Mice with Bioluminescent
Gram-Positive Bacteria
For oral efficacy testing experiments against S. aureus, bioluminescent ATCC12600
strain (Xen29, PerkinElmer) was used as described previously [25,38], but with some modi-
fications. Bacteria were grown in LB broth at 37 ◦C to A600 nm of 0.5 (equivalent to approx.
1.5 × 108 CFU/mL). Three groups of mice (n = 6 mice per group) were challenged IP
with approx. 2.5 × 107 CFU (first experiment) or approx. 1 × 107 CFU (second experi-
ment) of Xen29 in 200 µL PBS containing 3% hog gastric mucin type III (Sigma Aldrich,
NSW, Australia). At 2 h post-infection, approx. 50 µL of blood was withdrawn from
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the submandibular plexus of all mice for bacterial enumeration after which they were
subjected to bioluminescence imaging in both ventral and dorsal positions on the IVIS
Lumina XRMS Series III system (Caliper LifeSciences, hopkinton, MA, USA). Immediately
thereafter, group 1 mice received 25 µL of PBS orally, group 2 mice received 125 µL of
TCBZ at 50 mg/kg orally and group 3 mice received 94 µL of moxifloxacin orally. At
6 h, 10 h, 18 h and at 72 h post-infection (or during humane killing of moribund mice),
approx. 50 µL blood was again withdrawn, followed by bioluminescence imaging. After
imaging at 6 h post-infection, a second dose of PBS/TCBZ/moxifloxacin was administered.
Further treatments were given at 10 h, 18 h and 24 h post-infection. Mice were monitored
frequently (every 4 h) for signs of distress throughout the experiment, and the clinical
conditions were recorded on a clinical record sheet approved by The University of Adelaide
Ethics Committee. Mice that had become moribund or showed any evidence of distress
were humanely euthanized by cervical dislocation.
The first experiment showed a lack of efficacy for TCBZ post-24 h, which was partly
due to the high bacterial challenge dose. Therefore, a repeat experiment using a lower
bacterial dose (1 × 107 of Xen29) (n = 6 mice per group) was carried out as described above.
In both experiments, signals were collected from a defined region of interest and total
flux intensities (photons/s) were analyzed using Living Image Software 4.5. Differences
in luminescence signals between control and drug-treated groups were compared by the
Mann–Whitney U test (one-tailed).
3. Results
3.1. TCBZ Derivatives Demonstrate Antibacterial Activity
The potential of TCBZ as an antibacterial agent was initially examined by conducting
MIC testing of five of its derivatives against two VRE isolates and two S. aureus isolates.
The MIC determination showed that three of the five analogs possessed antimicrobial
activity against the four Gram-positive isolates selected (Table 1).











TCBZ * Triclabendazole, 2-methyl thio 4 8 2 2
TCBZ-SO * Triclabendazole,2-methylsulphoxide 16 16 8 8
TCBZ-SO2
Triclabendazole,
2-methylsulphone >256 >256 8 >256
TCBZ-SH * Triclabendazole, 2 thio 16 8 2 4
TCBZ-OH Triclabendazole, 2-hydroxy >256 >256 >256 >256
Ampicillin Ampicillin 0.125 0.5 <0.125 64
MIC test was performed in duplicate. *, Compounds selected for further screening.
MICs were repeated with the parent compound (TCBZ) and its thiol (TCBZ-SH) and
sulphoxide (TCBZ-SO) derivatives showing promising activity against three VRE, three
MRSA and two S. pneumoniae isolates, essentially confirming the initial results (Table 2).
Notably, only TCBZ showed antimicrobial activity against both S. pneumoniae isolates.
Therefore, TCBZ was chosen as the most promising analog for further evaluation.
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VRE35C 4 32 16
VRE60FR 8 32 16
VRE252 4 16 16
MRSA USA 300 2 8 2
MSSA 49775 2 8 2
MRSA 610 2 16 2
S. pneumoniae A66.1 16 >64 >64
S. pneumoniae D39 16 >64 >64
3.2. TCBZ Shows Antimicrobial Activity against an Expanded Range of Staphylococcus spp. and
Vancomycin-Resistant Enterococci
Given the promising antibacterial activity of TCBZ in the initial screen, its spectrum of
activity was further investigated against a range of clinical coagulase-positive Staphylococcus
spp., including human MRSA (n = 20; Table 3 and Table S2) and canine MRSP (n = 13;
Table S3) isolates. TCBZ inhibited the growth of all tested S. aureus and S. pseudintermedius
including MRSA and MRSP isolates at concentrations ranging from 2–4 µg/mL. The
MBC values of TCBZ against the S. aureus and S. pseudintermedius isolates were between
1–4 times the MIC values, confirming that TCBZ is bactericidal against coagulase-positive
Staphylococcus spp. (Table S3). However, in the presence of UHT milk, TCBZ did not
show any antimicrobial activity against S. aureus ATCC29213 at the highest concentration
(64 µg/mL) tested.
Table 3. MIC values for TCBZ against 20 MRSA isolates.
Compound
Concentration (µg/mL)
MIC range MIC50 MIC90 MBC
TCBZ 2–4 2 4 2–16
Daptomycin 0.25–1 0.5 0.5 ND
ND, not determined.
3.3. TCBZ Shows Limited Antimicrobial Activity against Streptococcus spp. Causing
Bovine Mastitis
We initially obtained a MIC of 16 µg/mL activity for TCBZ against two S. pneumoniae
clinical isolates. Therefore, further evaluation of its activity against other streptococci
causing bovine mastitis (S. uberis, S. agalactiae and S. dysgalactiae) was conducted. However,
no antimicrobial activity was detected for these streptococci, except for a single isolate of S.
dysgalactiae (MIC and MBC both 32 µg/mL). In addition, the effect of ultra-heat-treated
(UHT) milk in CAMHB medium and pH (RPMI medium) on the MIC of TCBZ against
the S. uberis, S. agalactiae and S. dysgalactiae isolates was also determined; however, no
antimicrobial activity was detected.
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3.4. TCBZ in Combination with PMB Demonstrates Synergistic Activity against a Range of
Gram-Negative ESKAPE Pathogens
The antimicrobial activity of TCBZ in the presence of PMB was investigated against a
range of clinical and reference human ESKAPE pathogens. These included E. coli strains
ATCC 10763 and ATCC 25922, P. aeruginosa strain PAO1, K. pneumoniae strains ATCC 33495
and ATCC 4352, A. baumannii strains ATCC 19606 and ATCC 12457, N. meningitidis clinical
isolates 423 and 424 as well as N. gonorrhoeae strains ATCC 16599 and ATCC 49226. The
combination of TCBZ and PMB resulted in a synergistic interaction against all the isolates
tested except for N. meningitidis and N. gonorrhoeae (Table 4).








PMB TCBZ PMB: TCBZ
E. coli ATCC 10763 0.5 >256 0.125:0.25 Synergism (0.25) 4:1024
E. coli ATCC 25922 0.5 >256 0.125:0.125 Synergism (0.25) 4:2048
P. aeruginosa PAO1 0.5 >256 0.125:2 Synergism (0.25) 4:128
K. pneumoniae ATCC 33495 0.5 >256 0.125:1 Synergism (0.25) 4:256
K. pneumoniae ATCC 4352 0.5 >256 0.125:1 Synergism (0.25) 4:256
A. baumannii ATCC 19606 1 >256 0.125:0.5 Synergism (0.125) 8:512
A. baumannii NCIMB 12457 1 >256 0.125:1 Synergism (0.125) 8:256
N. meningitidis 423 >256 32 4:16 Additivity (0.516) 64:2
N. meningitidis 424 >256 32 4:16 Additivity (0.516) 64:2
N. gonorrhoeae ATCC 16599 >256 >256 4:32 Additivity (0.516) 64:8
N. gonorrhoeae ATCC 49226 >256 >256 4:32 Additivity (0.516) 64:8
MIC, minimum inhibitory concentration. a FICI, fractional inhibitory concentration index: synergistic, FICI ≤ 0.5; additive, 0.5 < FICI ≤ 1;
indifferent, 1 < FICI ≤ 4; and antagonistic, FICI > 4. b DRI, dose-reduction index.
The antimicrobial activity of the TCBZ and PMB combination was tested against a
larger collection of human ESKAPE pathogens (18 K. pneumoniae clinical isolates plus ATCC
33495 and ATCC 4352, 18 E. coli clinical isolates plus ATCC 10763 and ATCC 25922, 16
A. baumannii clinical isolates plus A. baumannii ATCC 19606 and NCIMB 12457 as well as
19 P. aeruginosa clinical isolates plus PAO1) (Table 5). The results reveal a synergistic or
additive interaction of TCBZ and PMB against all Gram-negative isolates tested (reducing
the MIC of TCBZ by 16- to 2048-fold against all Gram-negative species tested).
Table 5. MIC range, MIC50 and MIC90 values for TCBZ and PMB alone and in combination against 20 E. coli, 20 K. pneumoniae,







PMB TCBZ PMB TCBZ PMB TCBZ
E. coli
(n = 20)
MIC range 0.125–1 >256 0.06–0.125 0.25–2 2–8 128–2048
MIC50 0.5 >256 0.125 0.5 4 512
MIC90 0.5 >256 0.125 1 Synergism (0.25) 4 256
K. pneumoniae
(n = 20)
MIC range 0.125–1 >256 0.06–0.5 0.5–16 2–8 16–512
MIC50 0.5 >256 0.25 4 2 64
MIC90 1 >256 0.5 8 Additivity (0.53) 2 32
A. baumannii
(n = 18)
MIC range 0.5–1 >256 0.125–0.125 0.5–2 4–8 128–512
MIC50 1 >256 0.125 2 8 128
MIC90 1 >256 0.125 2 Synergism (0.13) 8 128
P. aeruginosa
(n = 20)
MIC range 0.25–1 >256 0.06–0.25 0.125–4 2–4 64–2048
MIC50 0.5 >256 0.125 2 4 128
MIC90 0.5 >256 0.25 4 Additivity (0.516) 2 64
MIC, minimum inhibitory concentration. a FICI, fractional inhibitory concentration index: synergistic, FICI ≤ 0.5; additive, 0.5 < FICI ≤ 1;
indifferent, 1 < FICI ≤ 4; and antagonistic, FICI > 4. b DRI, dose-reduction index.
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3.5. TCBZ Kinetic Assays Confirm Bactericidal Activity
TCBZ was further investigated in kinetic assays to measure the time- and concentration-
dependent activity against S. aureus Xen 29 (Figure 2A,B), S. aureus ATCC 29213 (Figure 2C,D),
MRSA USA300 (Figure 2E,F), and MRSP-1 (Figure 2G,H), using norfloxacin or amikacin
as a comparator. The results confirm the MBC results showing that TCBZ is bactericidal
against Staphylococcus spp.
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The synergistic activity of TCBZ in combination with PMB against Gram-negative
bacteria was further evaluated in a time-kill assay using E. coli ATCC 25922. PMB/TCBZ at
0.25/0.25 µg/mL and at 0.5/0.5 µg/mL showed no antimicrobial activity while PMB/TCBZ
at 1/1 µg/mL reduced the CFU/mL by 6 × log10 by 4 h post-treatment and totally cleared
the bacteria, which demonstrated that TCBZ was bactericidal in the combination against
E. coli ATCC 25922 (Figure 3).
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Multi-sub-cultu resistance selection was con ucted to determine if TCBZ-resistant
utants coul d velop. For this assay, 21 daily sequential in vitro sub-cultur s were per-
for ed with TCBZ against S. aureus ATCC 29213, using enrofloxacin as a control antibiotic.
After 21 days, no TCBZ-resistant mutants were identified. However, enrofloxacin-resistant
mutants (2 × the MIC) had developed by day five and increased gradually to 16 × MIC by
days 18–21 (Figure 4).
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Figure 4. Resistance development of S. aureus ATCC 29213 to TCBZ. S. aureus ATCC 29213 was
challenged with TCBZ at a concentration range of 0.25 to 8 µg/mL over 21 daily sequential in vitro
sub-cultures. Enrofloxacin was used as a control antibiotic.
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3.7. Intracellular MIC Testing of TCBZ Shows Bacteriostatic Activity against S. aureus but
Bactericidal Activity against MRSP
The intracellular activity of TCBZ against S. aureus ATCC 29213 and two MRSP isolates
was examined in the mouse J774A.1 macrophage cell line. TCBZ was found to be bacte-
riostatic against intracellular S. aureus ATCC 29213 (Figure 5A). TCBZ exerted the lowest
effect on intracellular bacteria with a maximal decrease in bacterial counts of approximately
0.2 log10 at a concentration of 8 × MIC. By contrast, the positive control antimicrobial
(monensin) revealed a slowly developing bactericidal effect towards intracellular S. aureus
ATCC 29213 that was concentration dependent. Monensin showed a decrease in bacterial
counts of approximately 1.1 log10 at 8 × MIC in broth. Monensin showed a 0.5 log10
decrease in intracellular bacterial counts when examined at 1 × MIC (2 µg/mL) in broth
(Figure 5B).
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Figure 5. Intracellular activity of TCBZ using mouse J774A.1 macrophage cell line. (A) Intracellular
activity of TCBZ against S. aureus ATCC 29213; (B) intracellular activity of monensin against S. aureus
ATCC 29213; (C) intracellular activity of TCBZ against MRSP 1; and (D) intracellular activity of TCBZ
against MRSP 2.
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The intracellular activity of TCBZ against two MRSP isolates (isolate 1 and 2) was also
examined. At the highest concentration used (32 µg/mL (16 × MIC)), TCBZ showed a
bactericidal effect with a decrease in bacterial counts of 1.1 log10 and 1.4 log10 for isolate 1
and isolate 2, respectively (Figure 5C,D). Intracellular MRSP isolates were unaffected by
TCBZ when cells were incubated with a drug concentration equal to 1 × MIC (2 µg/mL).
3.8. TCBZ Is Non-Hemolytic and Non-Cytotoxic
A hemolytic activity assay for TCBZ against fresh human RBCs from donors showed
that it is non-hemolytic, with a hC50 higher than 128 µg/mL. Cytotoxic assay results
also show that the IC50 value for TCBZ was greater than the highest concentration tested
(16 µg/mL) against the MCF-7 (human breast cancer) cell line, suggesting non-cytotoxicity
against this cell line, while the IC50 values were 16 µg/mL against the hEK293 (human
embryonic kidney) and Detroit 562 (human pharyngeal epithelial) cell lines, suggesting
limited cytotoxicity against these two cell lines.
3.9. TCBZ Shows Oral Safety in Mice
Safety studies performed on mice using three doses of either 10 mg/kg or 50 mg/kg
TCBZ orally daily for 5 days showed no significant pathological changes in the lungs, heart,
liver, spleen, kidneys or small intestine of the treated groups compared to the group treated
with a similar dosing regimen of 1.6 mg/mL of moxifloxacin or the control group treated
with PBS.
3.10. Treatment of Mice with TCBZ Reduces S. aureus Population with Repeated Treatments
within 24 h Post-Infection
We evaluated the potential of TCBZ as an oral drug against systemic S. aureus infection,
using a well-characterized luminescent strain (Xen29) [25,38], by photon intensity mea-
surements. In the first experiment, mice were challenged IP with 2.5 × 107 CFU of Xen29
and treated with TCBZ at 50 mg/kg or with moxifloxacin at 6 mg/kg orally (administered
at 2, 6, 10 and 18 h post-infection), with untreated mice receiving an identical course of
PBS orally. The TCBZ treatment regimen resulted in a statistically significant reduction
in S. aureus populations at 10 and 18 h post-infection (p = 0.0483 and p = 0.0296, respec-
tively; Mann–Whitney U test, one-tailed) compared to the PBS control group. However,
the S. aureus populations gradually increased from 24 h post-infection upon withdrawal of
TCBZ treatment, consistent with a bacteriostatic action (not shown). Furthermore, mice
were found to have severe breathing difficulties and were reluctant to move from 36 h
post-infection onwards. Therefore, the mice were humanely killed, blood samples were
collected, and no bioluminescent total flux values were recorded for these time points.
By contrast, oral administration of moxifloxacin (drug control) resulted in a statistically
significant reduction in S. aureus populations at 6, 10 and 18 h post-infection (p = 0.0042;
p = 0.0125 and p = 0.0006, respectively; Mann–Whitney U test, one-tailed) and there was no
regrowth of the bacterial population post-moxifloxacin withdrawal (Figure 6), illustrated
by images of representative mice at selected time points (Figure 7).
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107 CFU of bioluminescent S. aureus Xen29 (n = 6) (treated at 2, 6, 10 and 18 h post-infection). Mice 88 
were subjected to bioluminescence imaging on IVIS Lumina XRMS Series III system. Dashed hori-89 
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(1 × 107 of Xen29) was carried out. In this experiment, repeated treatment with TCBZ at 50 94 
mg/kg up to 24 h post-infection (administered at 2, 6, 10, 18, and 24 h post-infection) also 95 
resulted in a gradual reduction in S. aureus populations. However, this reduction was not 96 
statistically significant compared to the untreated (PBS) control group (Figure S1). By con-97 
trast, oral administration of moxifloxacin (drug control) resulted in a statistically signifi-98 
cant reduction in S. aureus populations at 18 h post-infection (p = 0.0014 and p = 0.0031, 99 
respectively, Mann–Whitney U test) and there was no regrowth of the bacterial popula-100 
tion post-moxifloxacin withdrawal (Figure S1). 101 
Figure 6. Luminescence signal comparison between groups of CD1 mice challenged IP with 2.5 × 107
CFU of biolu inescent S. aureus Xen29 (n = 6) (treated at 2, 6, 10 and 18 h post-infection). Mice were
subjected to bioluminescence imaging on IVIS Lumina XRMS Series III system. Dashed horizontal
line indicates limit of detection (2.0 × 104 photons/s). Data are mean (±SEM) photons/s. * p < 0.05;
** p < 0.01; *** p < 0.001; ns = not significant; Mann–Whitney U test, one-tailed.
We attributed the overall lack of efficacy for TCBZ post-24 h to be partly due to
the high bacterial challenge dose. Therefore, a repeat experiment using a lower bacterial
dose (1 × 107 of Xen29) was carried out. In this experiment, repeated treatment with
TCBZ at 50 mg/kg up to 24 h post-infection (administered at 2, 6, 10, 18, and 24 h post-
infection) also resulted in a gradual reduction in S. aureus populations. However, this
reduction was not statistically significant compared to the untreated (PBS) control group
(Figure S1). By contrast, oral administration of moxifloxacin (drug control) resulted in a
statistically significant reduction in S. aureus populations at 18 h post-infection (p = 0.0014
and p = 0.0031, respectively, Mann–Whitney U test) and there was no regrowth of the
bacterial population post-moxifloxacin withdra al (Figure S1).
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registration of several new drugs that are ctive against Gram-positive and some Gra -
negative p hogens; however, antimicrobial a cess through t e ter m mbrane barrier of
Gram-negative bacteria still remain an important challenge [37,41,42]. Drugs in advanced
clinical development include modification of existing antibiotic classes, new antibiotic
classes, well-known combinations or novel drugs with adjuvants. Other recent and promis-
ing a proaches include repurposing old compounds with known safety a d developme t
pathways as new antimicrobial classes with potentially novel mechanisms of action [21], an
approach taken here. In developing new broad-spectrum antimicrobial agents that can over-
come the permeability barrier in Gram-negative bacterial pathogens [31,43,44], one strategy
being employed is combination of antibiotics with outer membrane permeabilizers [45].
In this work, we evaluated the antibacterial potential of TCBZ, a benzimidazole an-
thelmintic agent, which is the active ingredient of registered drugs for treating liver fluke in
animals (Fasciola spp.) and lung fluke in humans (Paragonimus spp.). TCBZ was previously
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suggested as a potential antibacterial agent in a repurposing study involving the mass
screening of FDA-registered drugs [21]; however, it was not until quite recently that it was
demonstrated to have potent antimicrobial activity against C. difficile as well as being active
against representative strains of normal human gut microbiota [22]. In our study, a range
of TCBZ derivatives were generated for an initial screen to identify the candidate with
the best antibacterial activity. An investigation of the antibacterial activity of a family of
TCBZ analogs incorporating the synthetic precursor thiol, TCBZ’s sequential oxidation
sulphoxide (TCBZ-SO) and sulphone (TCBZ-SO2), together with the final hydrolytic prod-
uct (TCBZ-OH), highlighted that the bioactivity is not restricted to the parent anthelmintic
but extends to its recognised in vivo metabolites. From the initial screening of the com-
pound series, TCBZ was found to be the most promising derivative with antimicrobial
activity demonstrated against Gram-positive bacteria including methicillin-resistant strains,
as well as Gram-negative bacteria in the presence of an outer membrane permeabilizer.
This corroborates the previous report [22], but also expands the antibacterial spectrum of
activity of TCBZ.
The mechanism of action of TCBZ has not been fully clarified. However, in vitro
and/or animal infection studies using TCBZ and its active metabolites (sulphoxide and
sulfone) against Fasciola species point to its effect on multiple targets resulting in reduced
membrane potential, inhibition of tubulin function and protein and enzyme synthesis [43].
Interesingly, it appears the sulphoxide metabolite (which is largely predominant in human
plasma following pre-systemic biotransformation of TCBZ) has a delayed but more potent
effect on parasite motility than the parent TCBZ compound, leading to the suggestion that
TCBZ likely acts primarily through the sulphoxide metabolite [46]. It is likely that TCBZ
and its metabolites have a similar mechanism of action on the membrane of bacteria, and
this will be the subject of future investigations.
This study had four major findings. Firstly, TCBZ was bactericidal against a range of
methicillin-susceptible and methicillin-resistant Staphylococcus spp. and VRE, and was also
shown to maintain antimicrobial activity against intracellular Staphylococcus spp. in vitro.
Secondly, no resistance to TCBZ was developed by S. aureus after 21 daily sequential in vitro
sub-cultures, a desirable characteristic for its further exploration as a novel antimicrobial
class to treat acute bacterial infections. Thirdly, TCBZ inhibited the growth of key Gram-
negative ESKAPE pathogens including E. coli, K. pneumoniae, A. baumannii and P. aeruginosa
in the presence of sub-inhibitory concentrations of PMB, indicating that the antimicrobial
target is present in both Gram-positive and Gram-negative bacteria. Fourthly, repeated oral
treatment of mice infected with bioluminescent S. aureus with TCBZ significantly reduced
S. aureus populations within 24 h post-infection, but did not eliminate infection with the
selected dosage regimen.
TCBZ demonstrated bactericidal antimicrobial activity (MICs of 2 µg/mL and MBCs
ranging from 2–16 µg/mL) against a range of methicillin-susceptible and methicillin-
resistant strains of coagulase-positive Staphylococcus spp., including the canine commensal
pathogen Staphylococcus pseudintermedius. Here, MICs/MBCs established for TCBZ were
several-fold lower than previously reported for triclabendazole [21], but the same trends
were observed (low uniform MICs with MBCs several-fold higher). Furthermore, TCBZ was
active at higher concentrations against VRE and S. pneumoniae. Demonstrated intracellular
activity against S. aureus suggested that TCBZ may have potential as a treatment for bovine
mastitis, which is most commonly caused by S. aureus strains adapted for intracellular
survival within polymorphonuclear cells of the bovine mammary gland. However, the
promising activity shown against human streptococci did not extend to the three main
species of streptococci causing bovine mastitis (S. uberis, S. agalactiae and S. dysgalactiae)
and furthermore, antibacterial activity was not demonstrated in the presence of milk, a key
disqualifier for further development as an intramammary mastitis formulation.
Despite these potential drawbacks, an important finding of this work was the demon-
stration that S. aureus did not develop resistance following 21 serial sub-cultures in the
presence of sub-inhibitory concentrations of TCBZ. By comparison, serial stepwise resis-
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tance was observed for enrofloxacin, a registered fluoroquinolone for animal treatment with
broad-spectrum bactericidal antimicrobial activity. Stepwise resistance to fluoroquinolones
develops via the accumulation of point mutations in the chromosomal target genes [47].
In this context, our results may indicate that similar chromosomal point mutations in the
putative target gene/s of triclabendazole in bacteria may not result in resistance. However,
this needs to be further investigated as it is quite possible that point mutations conferring
resistance could arise under the right selection pressure. Whilst the exact mechanism of
action of triclabendazole in flukes remains to be determined, development of resistance in
Fasciola hepatica has been recently observed [43]. Further research such as use of differential,
timed exposure RNAseq, fluorescence-based protein and lipid binding experiments and
electron microscopy studies could potentially unlock the target/s and mechanism of action
of triclabendazole in susceptible bacteria.
The observed in vitro synergistic antimicrobial activity of TCBZ in combination with
sub-inhibitory concentrations of PMB against a large panel of Gram-negative human
ESKAPE pathogens provides additional opportunities for treatment of Gram-negative
infections in clinical settings whilst also reducing the amount of PMB needed for effective
targeting. Although it was previously reported that PMB is toxic for humans at a concen-
tration of 4 µg/mL, the lowest concentration required in combination with TCBZ ranged
from 0.0625 to 0.25 µg/mL, which is 64- to 16-fold lower than its cytotoxic dose [45,48].
The finding that multiple oral administrations of TCBZ to mice at 50 mg/kg over 5 days
was safe without any demonstrable clinical signs or observable morphological effects on
the main organs examined also provides the possibility of using PMB in combination with
TCBZ for human use after robust testing in animal models of infection. Additionally, the
fact that no resistance developed to TCBZ by S. aureus after 21 daily sequential in vitro
sub-cultures also suggests that its synergistic antimicrobial activity with PMB against
Gram-negative pathogens warrants further exploration for specific treatment of acute
Gram-negative bacterial infections. This will be of further benefit in the colistin resistance
era as polymyxins are among the last line of antimicrobials used to treat multidrug-resistant
Gram-negative bacterial infections.
The in vivo efficacy data show that repeated treatment of mice resulted in a substantial
reduction in S. aureus populations over the 24 h period, with regrowth occurring once
treatment was withdrawn. This result suggests that TCBZ is bacteriostatic when the effec-
tive concentration in vivo is low (possibly due to poor host cell membrane penetration)
and could further explain the in vitro intracellular MIC result of TCBZ against S. aureus
ATCC 29213, where it was also found to be bacteriostatic. It is known that neutrophils
are recruited to the site of invading bacterial pathogens by host pattern recognition re-
ceptors through recognition of lipoteichoic acid (LTA), a component of the cell wall of all
Gram-positive bacteria [49,50]. Cell-wall-active β-lactam antimicrobials such as imipenem,
flucloxacillin and cefamandole significantly enhance the release of LTA compared to pro-
tein synthesis, inhibiting drugs such as gentamicin and erythromycin [51]. Furthermore,
together with glycopeptides, rifamycins, lincosamides, quinolones and fosfomycin, these
β-lactam antibiotics can penetrate human neutrophils and kill and/or inhibit intracellular
S. aureus without adversely affecting neutrophil function [51]. By contrast, we hypothesise
that TCBZ does not target the bacterial cell wall and may not initiate release of LTA to the
same extent. It would therefore be informative to investigate if a combination of any of
these antibiotics with TCBZ could be synergistic in eradicating intracellular S. aureus.
5. Conclusions
In this study, we showed that TCBZ, a benzimidazole anthelmintic agent, is bacterici-
dal against coagulase-positive staphylococci, including S. aureus (including MRSA) and
S. pseudintermedius (including MRSP), at relatively low concentrations and demonstrates
good intracellular activity at higher concentrations. In addition, oral treatment of mice with
TCBZ after systemic S. aureus challenge resulted in a significant reduction in S. aureus pop-
ulations in the blood of mice up to 18 h post-infection compared to control (untreated) mice
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but did not clear the bacterial infection from the bloodstream, suggesting bacteriostatic
activity in vivo. Future studies of pharmacokinetics and dosage optimisation of TCBZ may
identify a reliable and effective oral administration regimen.
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